BNP/CALL/ELI LILLY & CO/450/0.1/20.12.24 | Market Closed - Deutsche Boerse AG 15:50:23 2024-07-03 EDT | ||
| 42.62 EUR | -2.43% |
|
| Current month | -3.00% | ||
| 1 month | +17.80% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 24-07-03 | 42.62 | -2.43% |
| 24-07-02 | 43.68 | -1.02% |
| 24-07-01 | 44.13 | +0.43% |
| 24-06-28 | 43.94 | +0.34% |
| 24-06-27 | 43.79 | +0.81% |
Delayed Quote Deutsche Boerse AG
Last update July 03, 2024 at 03:50 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
BNP Paribas
|
| WKN | PC0LTF |
| ISIN | DE000PC0LTF4 |
| Date issued | 2023-03-31 |
| Strike | 450 $ |
| Maturity | 2024-12-20 (170 Days) |
| Parity | 10 : 1 |
| Emission price | 1.68 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 44.64 € |
|---|---|
| Lowest since issue | 2.13 € |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
898.1
USD
Average target price
870.3
USD
Spread / Average Target
-3.10%
- Stock Market
- Warrants
- Warrant
